肺毒性药物诱导肺泡上皮细胞损伤作用的研究进展

摘要/Abstract

摘要： 肺毒性是临床用药中常见的不良反应,如博来霉素、丝裂霉素、甲氨蝶呤等化疗药物都会造成肺损伤,而肺泡上皮细胞损伤是肺毒性的重要表现形式。本文主要综述了几种常见肺毒性药物诱导肺泡上皮细胞损伤的作用及机制的研究进展。

中图分类号:

R595.3

贺海彪, 魏萍, 孙兆艳, 刘册家. 肺毒性药物诱导肺泡上皮细胞损伤作用的研究进展[J]. 中华养生保健, 2022, 40(17): 64-66.

[1] Martinez F J, Collard H R, Pardo A, et al.Idiopathic pulmonary fibrosis[J]. Nature Reviews Disease Primers,2017,3(1):17075.
[2] Meadors M, Floyd J, Perry M C.Pulmonary toxicity of chemotherapy[J]. Semin Oncol, 2006,33(1):98-105.
[3] Jablonski R P, Kim S J, Cheresh P, et al.SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis[J]. FASEB J, 2017,31(6):2520-2532.
[4] Liu T, De Los Santos F G, et al. The Bleomycin Model of Pulmonary Fibrosis[J]. Methods Mol Biol, 2017,1627:27-42.
[5] Simpson A B, Paul J, Graham J, et al.Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours[J]. Br J Cancer, 1998,78(8):1061-1066.
[6] Aoshiba K, Tsuji T, Nagai A.Bleomycin induces cellular senescence in alveolar epithelial cells[J]. European Respiratory Journal, 2003,22(3):436-443.
[7] Jiang C, Liu G, Luckhardt T, et al.Serpine 1 induces alveolar type II cell senescence through activating p53-p21-Rb pathway in fibrotic lung disease[J]. Aging Cell, 2017,16(5):1114-1124.
[8] Tian Y, Li H, Qiu T, et al.Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-kappaB activation[J]. Aging Cell, 2019,18(1):e12858.
[9] Schafer M J, White T A, Iijima K, et al.Cellular senescence mediates fibrotic pulmonary disease[J]. Nat Commun, 2017,8:14532.
[10] Zhang X, Zou Y, Liu Y, et al.Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells[J]. Mol Immunol, 2020, 125:15-22.
[11] Ma Z, Ma C, Zhang Q, et al.Role of CXCL16 in BLM-induced epithelial-mesenchymal transition in human A549 cells[J]. Respir Res, 2021,22(1):42.
[12] Takano M, Deguchi J, Senoo S, et al.Suppressive effect of quercetin against bleomycin-induced epithelial-mesenchymal transition in alveolar epithelial cells[J]. Drug Metab Pharmacokinet, 2020,35(6):522-526.
[13] Li X, Ma L, Huang K, et al.Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by Inhibiting the TGF-beta1 Signaling Pathway[J]. Int J Mol Sci, 2021,22(4):1985.
[14] Nakahira K, Pabon Porras M A, Choi AM.Autophagy in Pulmonary Diseases[J]. Am J Respir Crit Care Med, 2016,194(10):1196-1207.
[15] Summer R, Shaghaghi H, Schriner D, et al.Activation of the mTORC1/PGC-1 axis promotes mitochondrial biogenesis and induces cellular senescence in the lung epithelium[J]. Am J Physiol Lung Cell Mol Physiol, 2019,316(6):L1049-L1060.
[16] Rodriguez-Reyes M, Marco-Hernandez J, Castro-Rebollo P, et al.Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report[J]. J Oncol Pharm Pract, 2019, 25(3):739-742.
[17] Huang W X, Guo X X, Peng Z Z, et al.[Induction of robust senescence-associated secretory phenotype in mouse NIH-3T3 cells by mitomycin C][J]. Sheng Li Xue Bao, 2017,69(1):33-40.
[18] Zhang C, Lu W, Luo X, et al.Mitomycin C induces pulmonary vascular endothelial-to-mesenchymal transition and pulmonary veno-occlusive disease via Smad3-dependent pathway in rats[J]. Br J Pharmacol, 2021, 178(1):217-235.
[19] Winter S S, Dunsmore K P, Devidas M, et al.Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization[J]. J Clin Oncol, 2018,36(29):2926-2934.
[20] Xie L, Zhao T, Cai J, et al.Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells[J]. Onco Targets Ther, 2016,9:7115-7122.
[21] Vargas P, Giacaman P, Fernandez J, et al.Bullous pemphigoid associated with psoriasis: a good response to methotrexate[J]. An Bras Dermatol, 2019,94(2):224-226.
[22] Kremer J M, Alarcon G S, Weinblatt M E, et al.Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review[J]. Arthritis Rheum, 1997,40(10):1829-1837.
[23] Kalemci S, Topal Y, Celik S Y, et al.Silibinin attenuates methotrexate-induced pulmonary injury by targeting oxidative stress[J]. Exp Ther Med , 2015,10(2):503-507.
[24] Yamamoto A, Kawami M, Konaka T, et al.Anticancer Drug-Induced Epithelial-Mesenchymal Transition via p53/miR-34a axis in A549/ABCA3 Cells[J]. J Pharm Pharm Sci, 2019,22(1):516-524.
[25] Kawami M, Harabayashi R, Miyamoto M, et al.Methotrexate-Induced Epithelial-Mesenchymal Transition in the Alveolar Epithelial Cell Line A549[J]. Lung, 2016,194(6):923-930.
[26] Yamagami Y, Kawami M, Ojima T, et al.Role of plasminogen activator inhibitor-1 in methotrexate-induced epithelial-mesenchymal transition in alveolar epithelial A549 cells[J]. Biochem Biophys Res Commun, 2020, 525(3):543-548.
[27] Hamilton D Sr, Nandkeolyar S, Lan H, et al.Amiodarone: A Comprehensive Guide for Clinicians[J]. Am J Cardiovasc Drugs, 2020, 20(6):549-558.
[28] Feduska E T, Thoma B N, Torjman M C, et al.Acute Amiodarone Pulmonary Toxicity[J]. J Cardiothorac Vasc Anesth, 2020,35(5):1485-1494.
[29] Rotmensch H H, Liron M, Tupilski M, Laniado S:et al. Possible association of pneumonitis with amiodarone therapy[J]. Am Heart J, 1980, 100(3):412-413.
[30] Malaviya R, Kipen H M, Businaro R,et al.Pulmonary toxicants and fibrosis: innate and adaptive immune mechanisms[J]. Toxicol Appl Pharmacol, 2020,409:115272.
[31] Kanagaki S, Suezawa T, Moriguchi K, et al.Hydroxypropyl Cyclodextrin Improves Amiodarone-Induced Aberrant Lipid Homeostasis of Alveolar Cells[J]. Am J Respir Cell Mol Biol, 2021,64(4):504-514.
[32] Cantor J O, Osman M, Cerreta J M, et al.Amiodarone-induced pulmonary fibrosis in hamsters[J]. Exp Lung Res, 1984,6(1):1-10.
[33] Uhal B D, Wang R, Laukka J, et al.Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists[J]. Pharmacol Toxicol, 2003,92(2):81-87.
[34] Uhal B D, Zhang H, Abdul-Hafez A, et al.Amiodarone induces angiotensinogen gene expression in lung alveolar epithelial cells through activation protein-1[J]. Basic Clin Pharmacol Toxicol, 2007,100(1):59-66.
[35] Weng J, Chen H, Wu H, et al.Amiodarone induces epithelial-mesenchymal transition in A549 cells via activation of TGF-beta1[J]. Drug Chem Toxicol, 2020,43(4):415-422.
[36] Antoniou K M, Tsitoura E, Vasarmidi E, et al.Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care[J]. Curr Opin Pharmacol, 2021,57:71-80.
[37] Zhang Y, Lu P, Qin H, et al.Traditional Chinese medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential[J]. Biomed Pharmacother, 2021, 133:111072.
[38] Spagnolo P, Bonella F, Ryerson C J, et al.Shedding light on developmental drugs for idiopathic pulmonary fibrosis[J]. Expert Opin Investig Drugs, 2020,29(8):797-808.

肺毒性药物诱导肺泡上皮细胞损伤作用的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

本文评价

[1]	张森森, 张纳新. 胺碘酮肺损伤的临床特点及治疗预后[J]. 中华养生保健, 2024, 42(3): 1-4.
[2]	杨柳. 胺碘酮与西地兰治疗急诊危重症合并急性快速型心房颤动的效果对比[J]. 中华养生保健, 2023, 41(9): 170-172.
[3]	李敏辉. 胺碘酮在抢救心力衰竭伴快速心房颤动患者中的疗效探讨[J]. 中华养生保健, 2023, 41(1): 91-93.
[4]	陈永明. 胺碘酮在急诊冠心病合并快速心律失常治疗中的有效性及可行性探究[J]. 中华养生保健, 2022, 40(9): 52-55.
[5]	马玉洁. 美托洛尔联合胺碘酮在冠心病心律不齐患者中的治疗效果[J]. 中华养生保健, 2022, 40(5): 157-159.
[6]	王艳. 胺碘酮联合倍他乐克急诊治疗室性心律失常对患者心动过速发作次数的改善探讨[J]. 中华养生保健, 2022, 40(4): 139-142.
[7]	马丽娜, 孟婷, 蒋庆军, 李伏, 席少静. 伊布利特和胺碘酮在永久性心脏起搏器植入术后新发心房颤动中的应用疗效和安全性对比[J]. 中华养生保健, 2022, 40(22): 56-59.
[8]	刘江波. 分析院前急救中选择胺碘酮与盐酸普罗帕酮治疗阵发性室上性心动过速的临床疗效对比[J]. 中华养生保健, 2022, 40(16): 57-60.
[9]	孟玲丽，朱英娟，王春红. 胺碘酮联合美托洛尔治疗快速心律失常的临床效果及不良反应发生率分析[J]. 中华养生保健, 2021, 39(1): 165-167.
[10]	孟静，邹剑峰. 胺碘酮治疗心力衰竭伴快速房颤的短时效果分析[J]. 中华养生保健, 2021, 39(1): 190-191.
[11]	张亚江. 观察胺碘酮治疗心律失常患者的临床效果[J]. 中华养生保健, 2020, 38(5): 181-182.
[12]	隋薇. 卡维地洛+胺碘酮治疗心律失常的效果观察及超敏C反应蛋白水平影响分析[J]. 中华养生保健, 2020, 38(3): 195-196.
[13]	张云珊, 田伟盟. 胺碘酮联合美托洛尔用于冠心病心律失常临床治疗效果观察[J]. 中华养生保健, 2020, 38(2): 90-92.